Answers are grounded in this paper and cite their sources.
Background & Aims Most patients with hepatocellular carcinoma (HCC) have underlying chronic liver disease, which may be associated with survival outcomes. Mac-2 binding protein glycosylation isoform (M2BPGi) is a biomarker reflecting liver fibrosis status, which in turn may be associated with the survival rate of HCC treated with immune checkpoint inhibitors (ICIs), especially in areas where viral hepatitis is endemic. Methods From September 2017 to September 2022, 158 patients receiving ICIs treatment for unresectable HCC (uHCC) were prospectively enrolled, with baseline serum samples for M2BPGi measurement. Variables associated with overall survival (OS) were analyzed. After October 2022, additional 60 consecutive patients with uHCC were recruited for validation. Results In the training cohort, serum M2BPGi level correlated strongly with FIB-4, Child-Pugh class and ALBI grade. A M2BPGi cut-off value of 1.68 COI significantly predicted OS (hazard ratio: 1.992, 95% confidence interval: 1.369 – 2.900; p < 0.001). By incorporating baseline alpha-fetoprotein (≥ 100 ng/ml), M2BPGi (≥ 1.68 COI), portal vein invasion, and non-HBV infection, a new Mac-2 score was developed that effectively stratified OS (28.8, 13.6 and 8.3 months for score 0-1, 2 and 3-4; p < 0.001). The Mac-2 score demonstrated superior discrimination and calibration abilities (the highest AUROC, greatest homogeneity, and the lowest corrected Akaike information criterion value), and net reclassification improvement compared with CRAFITY score, ALBI grade, and Child-Pugh class. Conclusion Serum fibrosis marker M2BPGi correlates with liver reserves and survival in patients with HCC undergoing ICI-based immunotherapy. The new Mac-2 score may have better potential advantages in clinical application to these patients. Impact and implications Most HCC cases occur in patients with underlying liver fibrosis or cirrhosis, and the fibrotic microenvironment may influence the anti-tumor effects of immune checkpoint inhibitors. Serum M2BPGi reflects liver fibrosis status and liver reserve in HCC and is associated with survival outcomes in ICI-based immunotherapy. The novel Mac-2 score, based on baseline M2BPGi levels has the potential to enhance clinical application by aiding patient selection and guiding therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: